Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 13,012 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 13,012 shares of Disc Medicine stock in a transaction on Monday, December 30th. The stock was sold at an average price of $61.95, for a total transaction of $806,093.40. Following the transaction, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at approximately $4,464,426.75. This trade represents a 15.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Disc Medicine Trading Up 2.2 %

Shares of Disc Medicine stock opened at $63.82 on Friday. The company has a market cap of $1.90 billion, a PE ratio of -16.04 and a beta of 0.75. The company has a 50 day moving average of $61.89 and a 200-day moving average of $52.19. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15. Research analysts forecast that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Institutional Trading of Disc Medicine

Several large investors have recently bought and sold shares of IRON. Amalgamated Bank lifted its holdings in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Disc Medicine during the second quarter worth $129,000. Quest Partners LLC acquired a new position in shares of Disc Medicine during the third quarter worth $131,000. Finally, Quantbot Technologies LP bought a new position in shares of Disc Medicine in the 3rd quarter valued at $146,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on IRON shares. Stifel Nicolaus upped their price target on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a report on Tuesday, November 5th. Wedbush reaffirmed an “outperform” rating and issued a $83.00 price objective on shares of Disc Medicine in a report on Monday, December 9th. Jefferies Financial Group initiated coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price for the company. Finally, Scotiabank raised their price target on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Buy” and a consensus target price of $87.50.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.